HfS Blueprint Report: Pharmaceuticals Industry-Specific BPO

Jan 27, 2016 Barbra McGann

This HfS Research Blueprint: Pharmaceuticals Industry–Specific BPO Blueprint, looks at the evolution of Pharma BPO to “As-a-Service”—a market that is increasingly agile, collaborative, and consumer-centric. HfS considers this transition in outsourcing a move to the As-a-Service Economy, placing increasing value on diverse talent, analytics, and collaboration, as well as increasingly on platform-based services.


Thus, in this Blueprint we use the 8 Ideals of the As-a-Service Economy as a significant element of our service provider assessment methodology. The eight ideals describe the operations of service buyers and service buyers in a business outcome–focused outsourcing partnership.


Two of the significant ways that pharmaceuticals companies “touch” consumers are in the R&D process and through sales and marketing. Along these lines, the scope of the Blueprint is business process support for industry-specific Pharmaceutical Research & Development and Commercial Services, including clinical data management, pharmacovigilance, regulatory support, consumer experience management, and sales and marketing.


The report includes a comparative analysis of the innovation and execution capabilities of service providers in this market. The service providers in scope are multi-national, multi-functional service providers with industry-specific pharmaceuticals business process support capability in their portfolio: Accenture, Cognizant, Genpact, HCL, TCS, Tech Mahindra, and WNS.

HfS Blueprint Report: Pharmaceuticals Industry-Specific BPO

(67 Pages)

Premium Members, Sign In to Download this Research

Sign In

Premium Research

This research document is available to premium HFS subscribers. If you are interested in becoming one or learning more, please contact us online, or have us call you!